EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition

Cristina Gómez iD, Zerin Alimajstorovic, Nantia Othonos, Denise V Winter, Sarah White, Gareth G Lavery, Jeremy W Tomlinson, Alexandra J Sinclair, Alex Odermatt iD

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Cristina Gómez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: 11-beta-Hydroxysteroid Dehydrogenase Type 1, Glucocorticoids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose 11β‐Hydroxysteroid dehydrogenase‐1 (11β‐HSD1) catalyses the oxoreduction of cortisone to cortisol, amplifying levels of active glucocorticoids. It is a pharmaceutical target in metabolic disease and cognitive impairments. 11β‐HSD1 also converts some 7oxo‐steroids to their 7β‐hydroxy forms. A recent study in mice described the ratio of tauroursodeoxycholic acid (TUDCA)/tauro‐7oxolithocholic acid (T7oxoLCA) as a biomarker for decreased 11β‐HSD1 activity. The present study evaluates the equivalent bile acid ratio of glycoursodeoxycholic acid (GUDCA)/glyco‐7oxolithocholic acid (G7oxoLCA) as a biomarker for pharmacological 11β‐HSD1 inhibition in humans and compares it with the currently applied urinary (5α‐tetrahydrocortisol + tetrahydrocortisol)/tetrahydrocortisone ((5αTHF + THF)/THE) ratio. Experimental Approach Bile acid profiles were analysed by ultra‐HPLC tandem‐MS in blood samples from two independent, double‐blind placebo‐controlled clinical studies of the orally administered selective 11β‐HSD1 inhibitor AZD4017. The blood GUDCA/G7oxoLCA ratio was compared with the urinary tetrahydro‐glucocorticoid ratio for ability to detect 11β‐HSD1 inhibition. Key Results No significant alterations were observed in bile acid profiles following 11β‐HSD1 inhibition by AZD4017, except for an increase of the secondary bile acid G7oxoLCA. The enzyme product/substrate ratio GUDCA/G7oxoLCA was found to be more reliable to detect 11β‐HSD1 inhibition than the absolute G7oxoLCA concentration in both cohorts. Comparison of the blood GUDCA/G7oxoLCA ratio with the urinary (5αTHF + THF)/THE ratio revealed that both successfully detect 11β‐HSD1 inhibition. Conclusions and Implications 11β‐HSD1 inhibition does not cause major alterations in bile acid homeostasis. The GUDCA/G7oxoLCA ratio represents the first blood biomarker of pharmacological 11β‐HSD1 inhibition and may replace or complement the urinary (5αTHF + THF)/THE ratio biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

11-beta-Hydroxysteroid Dehydrogenase Type 1GlucocorticoidsAnimalsHumansMiceBile Acids and SaltsBiomarkersHydrocortisoneTetrahydrocortisol

Stichwörter der Autor:innen

11β-hydroxysteroid dehydrogenaseLC-MSbile acidbiomarkerdiseaseglucocorticoidinhibitor

Substanzen

11-beta-Hydroxysteroid Dehydrogenase Type 1Bile Acids and SaltsBiomarkersGlucocorticoidsHydrocortisoneTetrahydrocortisol

Autor:innen und Institutionen

  • Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Metabolic Neurology, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
  • Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.
  • Department for Biosciences, Nottingham Trent University, Nottingham, UK.
  • Department of Neurology, University Hospitals Birmingham, Birmingham, UK.

ORCID-Profile: Cristina Gómez, Alex Odermatt

Förderung

  • Medical Research Council
  • Swiss National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Gómez, C., Alimajstorovic, Z., Othonos, N., Winter, D. V., White, S., Lavery, G. G., Tomlinson, J. W., Sinclair, A. J., & Odermatt, A. (2024). Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition. British Journal of Pharmacology. https://doi.org/10.1111/bph.16251

Vancouver

Gómez C, Alimajstorovic Z, Othonos N, Winter DV, White S, Lavery GG, et al. Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition. British Journal of Pharmacology. 2024. doi:10.1111/bph.16251

BibTeX
@article{Gmez2024,
  author = {Gómez, Cristina and Alimajstorovic, Zerin and Othonos, Nantia and Winter, Denise V and White, Sarah and Lavery, Gareth G and Tomlinson, Jeremy W and Sinclair, Alexandra J and Odermatt, Alex},
  title = {Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16251}
}
Kostenlos starten →